Antibody drug conjugates or ADCs are highly targeted biopharmaceutical drugs, that combine monoclonal antibodies specific for surface antigens present on specific tumor cells with highly effective anticancer agents linked by chemical linkers.
In simple terms, antibody-drug conjugates deliver “deactivated” cytotoxins to cancer cells. Once inside the tumor cell – internalization – the cytotoxin regains its full – cancer-killing – cytotoxic activity. As a result, cell death occurs quickly.
There are thousands of cellular toxins derived from natural sources or synthesized chemically, but only a few are suitable as components in an antibody-drug conjugate (ADCs). Early ADCs were created using clinically approved chemotherapeutic drugs such as doxorubicin and methotrexate.
Global Antibody Drug Conjugates Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 225 million cases and 4.63 million deaths due to coronavirus (COVID-19) were reported till September 14, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Antibody Drug Conjugates
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global antibody drug conjugates market owing to the cancer screening discontinuation and postponed hospital visits on cancer stage migration and outcomes. For instance, according to the article published in The Lancet Oncology, July 2021, an ambidirectional cohort study was conducted at 41 cancer centers in India, that were members of the National Cancer Grid of India to compare oncology service provision between March 1, 2020 and May 31, 2020, with the same time period in 2019. The results of the cohort study held, showed that COVID-19 pandemic was discovered to have a significant impact on cancer care. During the pandemic, all aspects of care were reduced, including screening, diagnosis, treatment, palliative care, and follow-up. These reductions are likely to result in delayed diagnosis and suboptimal treatment for at least a portion of patients who would have been diagnosed with cancer during this time period.
The global antibody drug conjugates market is estimated to be valued at US$ 4.29 Bn in 2021, and is expected to exhibit a CAGR of 14.0% over the forecast period (2021-2028).
Figure 1: Global Antibody Drug Conjugates Market Share (%) Analysis, By Application, 2021
The increasing cases of breast cancer for which antibody drug conjugates are used as a treatment, is expected to drive growth of the market over the forecast period.
The emerging prevalence of breast cancer is expected to bolster the growth of global antibody drug conjugates market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2018, the U.S. reported 254,744 new cases of breast cancer in women, and 42,465 women died of the cancer. Moreover in 2018, out of 100,000 women, 127 women had new cases of breast cancer and 20 women died of cancer.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 4.29 Bn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 14.0% | 2028 Value Projection: | US$ 11.01 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics. |
||
| Growth Drivers: |
|
||
Research and Development Activities
Increase in the research and development activities is expected to provide lucrative growth of global antibody drug conjugates market. For instance, on December 07, 2020, ADC Therapeutics SA, a late-stage biotechnology company focused on oncology, announced the latest clinical data of its two leading projects, Loncastuximab-Tesirine (Lonca) and Camidanlumab-Tesirine (Cami) at the 62nd annual meeting of the American Society of Hematology (ASH) 2020. Loncastuximab Tesirine is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody directed against human Cluster of Differentiation (CD)19 and conjugated to a pyrrolobenzodiazepine (PBD) dimeric cytotoxin via a linker. Camidanlumab Tesirin is an antibody drug conjugate (ADC) consisting of a monoclonal antibody that binds to CD25, which is conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirin.
Global Antibody Drug Conjugates Market – Regional Analysis
On the basis of region, the global antibody drug conjugates market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global antibody drug conjugates market over the forecast period, owing to the new product launches or approvals. For instance, on April 23, 2021, ADC Therapeutics SA, a next-generation biotechnology company focused on oncology, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNLONTA (Loncastuximab Tesirinelpyl) for the treatment of relapsed or refractory large B-cell lymphoma. ZYNLONTA, a CD19-targeted antibody-drug conjugate received accelerated approval from the U.S. FDA based on its overall response rate.
Moreover, due to the increasing strategic partnerships within the market players, Asia Pacific is expected to witness a significant growth in global antibody drug conjugates market over the forecast period. For instance, on November 27, 2018, Zymeworks Inc., a clinical-stage biopharmaceutical company and BeiGene, Ltd., a commercial-stage biopharmaceutical company, announced that the two companies entered into a strategic partnership for clinical development and commercialization of bi-specific antibodies ZW25 and ZW49 HER2. Zymeworks had granted BeiGene the exclusive right to develop and commercialize the clinical stage bi-specific antibody candidate and its preclinical-stage bi-specific antibody drug conjugate (ADC) ZW49 in Asia (excluding Japan), Australia, and New Zealand.
Figure 2: Global Antibody Drug Conjugates Market Value (US$ Bn), by Region, 2021
Global Antibody Drug Conjugates Market – Competitive Landscape
Major players operating in the global antibody drug conjugates market include F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
Antibody Drug Conjugates (ADCs) are targeted medicines that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of antibody-drug conjugates is fairly straightforward. When a portion of the antibody-drug conjugate is administered intravenously and binds to a target antigen on the cell surface of the tumor cell, the complex is internalized. Internalized vesicles fuse with other vesicles and enter the endosome-lysosome pathway after internalization. In the lysosome, proteases digest the monoclonal antibody to release free payloads, which then cross the lysosome membrane to enter the cytoplasm and/or nucleus, where they bind to the target molecule, causing cell death.
Market Dynamics
Market players are involved in research and development activities, this could contribute to the growth of the global antibody drug conjugates market over the forecast period. For instance, on April 05, 2021, Exelixis, Inc., a commercially successful oncology-focused biotechnology company, announced that the U.S. Food and Drugs Administration (FDA) accepted their Investigational New Drug Application (IND) to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of XB002 in patients with advanced solid tumors. XB002, as a next-generation tissue factor-targeting antibody-drug conjugate (ADC), has the potential for a higher therapeutic index and a better safety profile than earlier-generation tissue factor-targeting ADCs.
Market players are focused on strategic collaborations and agreements, which is expected to propel the growth of the global antibody drug conjugates market. For instance, on June 17, 2021, Eisai Co., Ltd., a leading global R&D-based pharmaceutical company, and Bristol-Myers Squibb Company, a global biopharmaceutical company, announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the global antibody drug conjugates market. For instance, on September 13, 2020, Gilead Sciences, Inc., a research-based biopharmaceutical company, and Immunomedics, a leader in next-generation antibody-drug conjugate (ADC) technology, announced a definitive agreement under which Gilead will acquire Immunomedics for US$ 88.00 per share in cash. Under the terms of agreement, Gilead will be provided with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2020, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients